Search
Clinician Ordering Portal
Scientific evidence
Independent blinded validation of a tissue systems pathology test to predict progression in patients with Barrett’s esophagus
Jun 2020
A risk prediction test identifies patients with non-dysplastic Barrett's esophagus who are at high risk for progression to high-grade dysplasia or cancer.
Publication: American Journal of Gastroenterology
Clinical validity of a gene expression signature in diagnostically uncertain neoplasms
Jun 2020
A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.
Publication: Personalized Medicine
Gene expression profiling prognostication of posterior uveal melanoma
Jun 2020
Investigate the influence of tumor size by American Joint Committee on Cancer (AJCC) stage, Collaborative Ocular Melanoma Study (COMS) size, tumor largest basal diameter (LBD), and tumor thickness on prognostication by gene expression profiling (GEP) class.
Publication: Ophthalmology Retina
A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis
May 2020
Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.
Publication: SKIN: Journal of Cutaneous Melanoma
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict progression in community- based Barrett's esophagus with low-grade dysplasia: analysis in a completed prospective study
May 2020
TissueCypher may be a practical and effective solution to the lack of standardization of expert pathology review if LGD as advocated by all guidelines.
Publication: Podium presentation (1085) at DDW 2020, virtual
Prediction of neoplastic progression in Barrett’s esophagus by pathologic assessment of degree of crypt atypia and by TissueCypher
May 2020
TissueCypher provided superior risk stratification that outperformed crypt atypia scores.
Publication: Poster presentation (Sa1203) at DDW 2020, Virtual
Independent validation of TissueCypher to predict future progression in non- dysplastic Barrett’s esophagus: a spatial-temporal analysis
May 2020
An independent validation study showed TissueCypher identified a significant subset of NDBE patients who progress at a rate comparable to expert-confirmed LGD.
Publication: Poster presentation (Sa1189) at DDW 2020, Virtual
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma
Apr 2020
To develop and validate a gene expression profile (GEP) test for predicting risk for metastasis in localized, high-risk cSCC with the goal of improving risk-directed patient management.
Publication: JAAD
Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients
Mar 2020
Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.
Publication: Journal of the American Academy of Dermatology
Prospective evaluation of risk-appropriate management of uveal melanoma patients informed by gene expression profiling
Mar 2020
The multicenter Clinical Application of DecisionDx-UM Gene Expression Assay Results study provides prospective validation of the clinical utility of the 15-gene expression profile test in directing metastatic surveillance imaging, follow-up and referral patterns.
Publication: Melanoma Management